The door of the drugstore is not so easy to enter. The chairman of the drugstore happily ate a closed door.
Release time:
2021-12-23
"Your travel cassette *cannot enter the pharmacy."
12# May 14 , Jiang Xiaomeng, chairman of the group company, was stopped by the clerk when registering his personal information.
On the morning of the same day, Chairman Jiang Xiaomeng, Deputy General Manager Xiang Chongping and relevant department personnel from the headquarters went to the company's key units for epidemic prevention and control in the gold enterprise, the International Trade Company and the Peak Pharmacy, to check the implementation of epidemic prevention work. Shizhen Pavilion is the flagship store and image store of Jianfeng Pharmacy. It is located in the core of the urban area. It has a large scale and complicated personnel flow. Naturally, it has become the first choice for this special inspection. But unexpectedly, before entering the door, he was rejected by "merciless.
"My health code is a green code, my temperature is normal, and I'm wearing a mask, so I should be able to enter, right?" Jiang Xiaomeng went to Hangzhou on a business trip a few days ago, although he didn't go to the area where the epidemic occurred, the itinerary card was a little more than others.
"No. The new notice in the city, even if it is a green code, the itinerary cassette *cannot enter the pharmacy." Found a "dispute" at the door, a clerk hurried over to help explain, "all pharmacies are the same."
Seeing this scene, Xiang Chongping hurriedly stepped forward and said, "Don't you know each other? This is the leader of the group company. He came to your store to inspect the work today!" This "intercession" is clearly intentional. The clerk at
was somewhat embarrassed, but he still resolutely did not give in: "I know Mr. Jiang, but now is a special period, and we must implement the city's regulations."
After final inspection, Xiang Chongping and Li Xiaoyin, deputy manager of the audit performance department, had no abnormalities in their health codes, travel cards and body temperatures. After registering their personal information, they were allowed to enter Shizhen Pavilion and completed the epidemic prevention inspection.
was rejected. instead of being angry, Jiang xiaomeng praised the two employees who strictly controlled the "entry gate" with a smile: "you have such a strong awareness of epidemic prevention, which is good." Xiang Chongping also said after the inspection: "If every store is like this, we will be relieved." (Reporter Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page